The role of peroxisome proliferator-activated receptor γ in bladder cancer in relation to angiogenesis and progression

被引:16
|
作者
Possati, L [1 ]
Rocchetti, R
Talevi, S
Beatrici, V
Margiotta, C
Ferrante, L
Calza, R
Sagrini, D
Ferri, A
机构
[1] Univ Ancona, Dept Biomed Sci, I-60131 Ancona, Italy
[2] Hosp Fano, Dept Surg, Urol Unit, Fano, Italy
[3] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy
来源
关键词
D O I
10.1016/S0306-3623(01)00116-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peroxisome proliferator-activated receptor gamma (PPARgamma) immunohistochemical expression was analyzed in 75 human bladder tumor specimens, where the expression of some angiogenic factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived endothelial cell growth factor (PDECGF), and tumor progression markers, such as epidermal growth factor receptor (EGFr), p16, mutated p53, and normal pRB, were also analyzed. The results were then compared to the clinical and pathological characteristics of the disease. PPARgamma was expressed more significantly in papillary tumors than in solid cancers, and its presence was associated with statistical significance to low incidence of tumor recurrence or progression. This significant association was observed also when PPARgamma was expressed in the presence of PDECGF, which resulted, when considered alone, to an angiogenic factor typical of solid cancers and appeared related to poor prognosis. In the presence of bFGF, on the contrary, PPARgamma expression no longer resulted to a significant association with low incidence of tumor recurrence or progression, suggesting a possible worsening role of this angiogenic factor, typical of papillary cancers, in its interaction with PPARgamma. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [21] Peroxisome proliferator-activated receptor γ and lung cancer biology
    Roman, Jesse
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (02) : 528 - 533
  • [22] Peroxisome proliferator-activated receptor-γ and esophageal cancer
    Shimada, T
    Terano, A
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2002, 140 (01): : 4 - 5
  • [23] Peroxisome proliferator-activated receptor. and colorectal cancer
    Dai, Yun
    Wang, Wei-Hong
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 2 (03) : 159 - 164
  • [24] Peroxisome proliferator-activated receptor and epithelial ovarian cancer
    Yokoyama, Y.
    Mizunuma, H.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 31 (06) : 612 - 615
  • [25] Inhibition of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) reduces choroidal angiogenesis
    Savage, Sara R.
    Davia, Laura L.
    Penn, John S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [26] Peroxisome proliferator-activated receptor δ and gastric cancer (Review)
    Wu, Chung W.
    Yu, Jun
    Sung, Joseph J. Y.
    ONCOLOGY REPORTS, 2009, 22 (03) : 451 - 457
  • [27] Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis
    Giaginis, Costas
    Margeli, Alexandra
    Theocharis, Stamatios
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (10) : 1561 - 1572
  • [28] Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
    Tseng, Chin-Hsiao
    Tseng, Farn-Hsuan
    JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS, 2012, 30 (04): : 368 - 402
  • [29] Peroxisome proliferator-activated receptor γ and atherosclerosis
    Marx, N
    CURRENT HYPERTENSION REPORTS, 2002, 4 (01) : 71 - 77
  • [30] Peroxisome proliferator-activated receptor agonists
    Willson, TM
    Wahli, W
    CURRENT OPINION IN CHEMICAL BIOLOGY, 1997, 1 (02) : 235 - 241